A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOBEVIBART+ELEBSIRAN COMBINATION THERAPY IN PARTICIPANTS WITH CHRONIC HDV INFECTION (ECLIPSE 1)

Registry ID

VIR-CHDV-V203

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

VIR BIOTECHNOLOGY, INC.

Start date

2025-03-24

Last update

2025-03-20

Conditions

• HEPATITIS D

Related clinical trials

• A GLOBAL, RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 2B/3 TRIAL EVALUATING BJT-778 VS DELAYED TREATMENT FOR THE TREATMENT OF CHRONIC HEPATITIS DELTA INFECTION (AZURE-1)

View on source registry